Epirubicin, Cisplatin and Protracted Venous Infusion 5-Fluorouracil Chemotherapy for Advanced Salivary Adenoid Cystic Carcinoma

Abstract Aims Adenoid cystic carcinoma (ACC) is a rare tumour that usually arises in the salivary glands. Initial management is surgery often combined with adjuvant radiotherapy. Chemotherapy is reserved for treatment of symptomatic recurrence. We evaluated the combination of epirubicin, cisplatin a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oncology (Royal College of Radiologists (Great Britain)) 2009-05, Vol.21 (4), p.311-314
Main Authors: Ross, P.J, Teoh, E.M, A'Hern, R.P, Rhys-Evans, P.H, Harrington, K.J, Nutting, C.M, Gore, M.E
Format: Article
Language:English
Subjects:
Adenoid cystic carcinoma
Adult
Antibiotics, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Adenoid Cystic - drug therapy
Carcinoma, Adenoid Cystic - mortality
chemotherapy
Cisplatin - administration & dosage
Disease Progression
Epirubicin - administration & dosage
Female
Fluorouracil - administration & dosage
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Radiology
response rates
salivary gland
Salivary Gland Neoplasms - drug therapy
Salivary Gland Neoplasms - mortality
survival
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Adenoid cystic carcinoma (ACC) is a rare tumour that usually arises in the salivary glands. Initial management is surgery often combined with adjuvant radiotherapy. Chemotherapy is reserved for treatment of symptomatic recurrence. We evaluated the combination of epirubicin, cisplatin and protracted venous infusion 5-fluorouracil (ECF) in the management of ACC. Materials and methods Patients referred for treatment of advanced, symptomatic ACC were considered. The drugs given were epirubicin 50 mg/m2 3-weekly, cisplatin 60 mg/m2 3-weekly and protracted venous infusion 5-fluorouracil 200 mg/m2 /day. Results Eight patients (median age 46 years) received a median of five cycles of chemotherapy. All patients had had previous surgery, seven had had previous radiotherapy and one had had previous chemotherapy. One patient showed a partial response (duration 34 months) and five showed stable disease (median duration 13.6 months [6.8–15.9+ months]). Median survival was 27 months (3.5–62.3 months). Conclusions The activity of ECF in ACC of the head and neck seems to be similar to the combination of cisplatin and 5-fluorouracil and single-agent epirubicin.
ISSN:0936-6555
1433-2981
DOI:10.1016/j.clon.2008.12.009